Role of CD19 and specific KIT‐D816 on risk stratification refinement in t(8;21) acute myeloid leukemia induced with different cytarabine intensities

Clinical heterogeneity under induction with different dosages of cytarabine in core binding factor acute myeloid leukaemia

(2020) Biao Wang et al.   Scientific Reports

Negative CD19 expression is associated with inferior relapse-free survival in children with RUNX1-RUNX1T1 -positive acute myeloid leukaemia: results from the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 study

(2019) Kenichi Sakamoto et al.   BRITISH JOURNAL OF HAEMATOLOGY

Functional Properties of KIT Mutations Are Associated with Differential Clinical Outcomes and Response to Targeted Therapeutics in CBF Acute Myeloid Leukemia

(2019) Katherine Tarlock et al.   CLINICAL CANCER RESEARCH

Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology

(2019) Martin S. Tallman et al.   Journal of the National Comprehensive Cancer Network

Clonal interference of signaling mutations worsens prognosis in core-binding factor acute myeloid leukemia

(2018) Raphael Itzykson et al.   BLOOD

Monitoring of clonal evolution of double C-KIT exon 17 mutations by Droplet Digital PCR in patients with core-binding factor acute myeloid leukemia

(2018) Yanhong Tan et al.   LEUKEMIA RESEARCH

The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders

(2018) Robert Roskoski   PHARMACOLOGICAL RESEARCH

The immunophenotypic characteristics and flow cytometric scoring system of acute myeloid leukemia with t(8;21) (q22;q22); RUNX1-RUNX1T1

(2018) Lei Shang et al.   International Journal of Laboratory Hematology

Radotinib induces high cytotoxicity in c-KIT positive acute myeloid leukemia cells

(2017) Sook-Kyoung Heo et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Targeting c-KIT (CD117) by dasatinib and radotinib promotes acute myeloid leukemia cell death

(2017) Sook-Kyoung Heo et al.   Scientific Reports

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

(2016) Hartmut Döhner et al.   BLOOD

Comprehensive mutational profiling of core binding factor acute myeloid leukemia

(2016) N. Duployez et al.   BLOOD

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

(2016) D. A. Arber et al.   BLOOD

Genomic Classification and Prognosis in Acute Myeloid Leukemia

(2016) Elli Papaemmanuil et al.   NEW ENGLAND JOURNAL OF MEDICINE

Next-generation sequencing with a myeloid gene panel in core-binding factor AML showed KIT activation loop and TET2 mutations predictive of outcome

(2016) C Y Cher et al.   Blood Cancer Journal

Notch signalling drives bone marrow stromal cell-mediated chemoresistance in acute myeloid leukemia

(2016) Paul Takam Kamga et al.   Oncotarget

Systematic Classification of Mixed-Lineage Leukemia Fusion Partners Predicts Additional Cancer Pathways

(2016) Rolf Marschalek   Annals of Laboratory Medicine

Complex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up

(2015) Federico Mosna et al.   AMERICAN JOURNAL OF HEMATOLOGY

Additional chromosomal abnormalities in core-binding factor acute myeloid leukemia

(2015) H.H. Hsiao et al.   GENETICS AND MOLECULAR RESEARCH

Clinical Impact of Additional Cytogenetic Aberrations,cKITandRASMutations, and Treatment Elements in Pediatric t(8;21)-AML: Results From an International Retrospective Study by the International Berlin-Frankfurt-Münster Study Group

(2015) Kim Klein et al.   JOURNAL OF CLINICAL ONCOLOGY

Core-binding factor acute myeloid leukemia: Heterogeneity, monitoring, and therapy

(2014) Melhem Solh et al.   AMERICAN JOURNAL OF HEMATOLOGY

High number of additional genetic lesions in acute myeloid leukemia with t(8;21)/RUNX1-RUNX1T1: frequency and impact on clinical outcome

(2014) M-T Krauth et al.   LEUKEMIA

Exome sequencing identifies recurring FLT3 N676K mutations in core-binding factor leukemia

(2013) S. Opatz et al.   BLOOD

Sense and nonsense of high-dose cytarabine for acute myeloid leukemia

(2013) B. Lowenberg   BLOOD

The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia

(2013) C Allen et al.   LEUKEMIA

CD56 expression is an independent prognostic factor for relapse in acute myeloid leukemia with t(8;21)

(2013) Noriyoshi Iriyama et al.   LEUKEMIA RESEARCH

Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG)

(2012) P. Paschka et al.   BLOOD

Cytarabine Dose for Acute Myeloid Leukemia

(2011) Bob Löwenberg et al.   NEW ENGLAND JOURNAL OF MEDICINE

Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials

(2010) D. Grimwade et al.   BLOOD

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

(2009) J. W. Vardiman et al.   BLOOD

Nucleophosmin (NPM1) mutations in adult and childhood acute myeloid leukaemia: towards definition of a new leukaemia entity

(2009) Rachel Rau et al.   HEMATOLOGICAL ONCOLOGY

Patients With Acute Myeloid Leukemia andRASMutations Benefit Most From Postremission High-Dose Cytarabine: A Cancer and Leukemia Group B Study

(2008) Andreas Neubauer et al.   JOURNAL OF CLINICAL ONCOLOGY